A Study of Pegylated Liposomal Doxorubicin in Platinum-Refractory Epithelial Ovarian Cancer

Oncology ◽

10.1159/000081315 ◽

2004 ◽

Vol 67 (3-4) ◽

pp. 183-186 ◽

Author(s):

Sarikapan Wilailak ◽

Vasant Linasmita

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Platinum Refractory

Download Full-text

Faculty Opinions recommendation of Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028212.793483427 ◽

2013 ◽

Author(s):

Roberto Angioli

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer

Cancer Management and Research ◽

10.2147/cmar.s15558 ◽

2011 ◽

pp. 219 ◽

Author(s):

Maurie Markman

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Download Full-text

Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.04.708 ◽

2020 ◽

Vol 158 (2) ◽

pp. 309-315 ◽

Author(s):

Laura M. Chambers ◽

Adam Pendlebury ◽

Peter G. Rose ◽

Meng Yao ◽

Robert DeBernardo

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Second-Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD), Irinotecan, and Combination Therapies at Lower Doses

Ovarian Cancer - Clinical and Therapeutic Perspectives ◽

10.5772/28554 ◽

2012 ◽

Author(s):

Toru Sugiyama

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Second Line ◽

Combination Therapies ◽

Second Line Chemotherapy ◽

Line Chemotherapy

Download Full-text

Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5043 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5043-5043 ◽

Author(s):

T. Safra ◽

L. Borgato ◽

M. Nicoletto ◽

L. Rolnitzky ◽

J. Curtin ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Download Full-text

Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5064 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5064-5064 ◽

Author(s):

F. Muggia ◽

T. Safra ◽

L. Borgato ◽

A. Gandhi ◽

G. Mancinc ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.2582 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 2582-2582

Author(s):

M. D. Walsh ◽

H. Giovinazzo ◽

A. Sheikh ◽

M. Ivanovic ◽

A. B. Whitlow ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Sulfur Colloid ◽

Download Full-text

Treatment-related microangiopathic glomerulopathy and severe chronic kidney disease (CKD) in recurrent epithelial ovarian cancer (rEOC): A possible relationship with pegylated liposomal doxorubicin (PLD).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e15551 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e15551-e15551

Author(s):

M. Kwa ◽

R. A. Baumgartner ◽

L. Shavit ◽

I. Barash ◽

J. Michael ◽

...

Keyword(s):

Ovarian Cancer ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Severe Chronic Kidney Disease

Download Full-text

Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer

Nanomedicine Nanotechnology Biology and Medicine ◽

10.1016/j.nano.2015.05.007 ◽

2015 ◽

Vol 11 (7) ◽

pp. 1797-1807 ◽

Author(s):

Gina Song ◽

Teresa K. Tarrant ◽

Taylor F. White ◽

David A. Barrow ◽

Charlene M. Santos ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin

Download Full-text

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

European Journal of Cancer ◽

10.1016/j.ejca.2009.05.016 ◽

2009 ◽

Vol 45 (13) ◽

pp. 2324-2332 ◽

Author(s):

I. Vergote ◽

N. Finkler ◽

J. del Campo ◽

A. Lohr ◽

J. Hunter ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Pegylated Liposomal Doxorubicin ◽

Phase 3 ◽

Randomised Study ◽

Line Therapy ◽

Platinum Refractory ◽

Third Line Therapy ◽

Download Full-text